Pharmaceutical companies Moderna and Merck reported positive Phase 3 clinical trial results for their personalized mRNA cancer vaccine combined with immunotherapy, showing improved outcomes for advanced melanoma patients.
Key points
- The experimental treatment, called intismeran autogene, marks the first positive Phase 3 trial result for an individualized neoantigen and mRNA-based cancer therapy.
- The therapy was tested in combination with Merck's immunotherapy drug Keytruda in a study involving over 1,100 patients.
- Moderna CEO Stéphane Bancel and Merck representatives noted the treatment significantly improved recurrence-free survival and delayed distant metastasis after surgery.
- Following the announcement, Moderna's stock surged significantly while Merck shares also saw gains on the stock market.
Why it matters
This milestone represents a major breakthrough in oncology, demonstrating the first successful late-stage trial for a personalized messenger ribonucleic acid cancer therapy aimed at preventing melanoma recurrence.
Comments (1)
Incroyable @xuesheng